File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

TitleEffects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
Authors
Issue Date2004
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcv
Citation
Journal Of Clinical Virology, 2004, v. 31 n. 4, p. 304-309 How to Cite?
AbstractThe effect of corticosteroid treatment on the viral load of Severe Acute Respiratory Syndrome (SARS) patients is unknown. To compare the plasma SARS-CoV RNA concentrations in ribavirin-treated patients who received early hydrocortisone therapy with those who received placebo. Serial plasma SARS-CoV RNA concentrations measured in the setting of a prospective, randomized double-blinded, placebo-controlled trial designed to assess the efficacy of "early" (<7 days of illness) hydrocortisone use in previously healthy SARS patients were analyzed. SARS-CoV RNA was quantified using a one-step real-time RT-PCR assay targeting the nucleocapsid gene. Among 16 non-ICU cases, SARS-CoV RNA was detected in plasma since day 3-4 after fever onset; viral concentration peaked in the first week, which then rapidly declined in the second week of illness. On days 8, 12, 16, and 20, the cumulative proportion of patients with undetectable virus in plasma was 31%, 69%, 92%, and 100%, respectively. Plasma SARS-CoV RNA concentrations in the second and third week of illness were significantly higher in patients who received initial hydrocortisone treatment (n = 9), as compared to those who received placebo (n = 7)(AUC; Mann-Whitney, P = 0.023). The median time for SARS-CoV to become undetectable in plasma was 12 days (11-20 days) versus 8 days (8-15 days), respectively. Our findings suggested "early" corticosteroid treatment was associated with a higher subsequent plasma viral load. © 2004 The Chinese University of Hong Kong. Published by Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/172982
ISSN
2015 Impact Factor: 2.647
2015 SCImago Journal Rankings: 1.503
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLee, Nen_US
dc.contributor.authorAllen Chan, KCen_US
dc.contributor.authorHui, DSen_US
dc.contributor.authorNg, EKOen_US
dc.contributor.authorWu, Aen_US
dc.contributor.authorChiu, RWKen_US
dc.contributor.authorWong, VWSen_US
dc.contributor.authorChan, PKSen_US
dc.contributor.authorWong, KTen_US
dc.contributor.authorWong, Een_US
dc.contributor.authorCockram, CSen_US
dc.contributor.authorTam, JSen_US
dc.contributor.authorSung, JJYen_US
dc.contributor.authorLo, YMDen_US
dc.date.accessioned2012-10-30T06:26:12Z-
dc.date.available2012-10-30T06:26:12Z-
dc.date.issued2004en_US
dc.identifier.citationJournal Of Clinical Virology, 2004, v. 31 n. 4, p. 304-309en_US
dc.identifier.issn1386-6532en_US
dc.identifier.urihttp://hdl.handle.net/10722/172982-
dc.description.abstractThe effect of corticosteroid treatment on the viral load of Severe Acute Respiratory Syndrome (SARS) patients is unknown. To compare the plasma SARS-CoV RNA concentrations in ribavirin-treated patients who received early hydrocortisone therapy with those who received placebo. Serial plasma SARS-CoV RNA concentrations measured in the setting of a prospective, randomized double-blinded, placebo-controlled trial designed to assess the efficacy of "early" (<7 days of illness) hydrocortisone use in previously healthy SARS patients were analyzed. SARS-CoV RNA was quantified using a one-step real-time RT-PCR assay targeting the nucleocapsid gene. Among 16 non-ICU cases, SARS-CoV RNA was detected in plasma since day 3-4 after fever onset; viral concentration peaked in the first week, which then rapidly declined in the second week of illness. On days 8, 12, 16, and 20, the cumulative proportion of patients with undetectable virus in plasma was 31%, 69%, 92%, and 100%, respectively. Plasma SARS-CoV RNA concentrations in the second and third week of illness were significantly higher in patients who received initial hydrocortisone treatment (n = 9), as compared to those who received placebo (n = 7)(AUC; Mann-Whitney, P = 0.023). The median time for SARS-CoV to become undetectable in plasma was 12 days (11-20 days) versus 8 days (8-15 days), respectively. Our findings suggested "early" corticosteroid treatment was associated with a higher subsequent plasma viral load. © 2004 The Chinese University of Hong Kong. Published by Elsevier B.V. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcven_US
dc.relation.ispartofJournal of Clinical Virologyen_US
dc.subject.meshAdrenal Cortex Hormones - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAdulten_US
dc.subject.meshCoronavirus - Geneticsen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshHumansen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRna, Viral - Blooden_US
dc.subject.meshSars Virus - Genetics - Physiologyen_US
dc.subject.meshSevere Acute Respiratory Syndrome - Blood - Diagnosis - Drug Therapyen_US
dc.subject.meshViral Loaden_US
dc.titleEffects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patientsen_US
dc.typeArticleen_US
dc.identifier.emailNg, EKO: ngko@hku.hken_US
dc.identifier.authorityNg, EKO=rp01364en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.jcv.2004.07.006en_US
dc.identifier.pmid15494274-
dc.identifier.scopuseid_2-s2.0-5644261635en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-5644261635&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume31en_US
dc.identifier.issue4en_US
dc.identifier.spage304en_US
dc.identifier.epage309en_US
dc.identifier.isiWOS:000225200300012-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridLee, N=7402722286en_US
dc.identifier.scopusauthoridAllen Chan, KC=6503912692en_US
dc.identifier.scopusauthoridHui, DS=7101862411en_US
dc.identifier.scopusauthoridNg, EKO=21135553700en_US
dc.identifier.scopusauthoridWu, A=7402998681en_US
dc.identifier.scopusauthoridChiu, RWK=7103038413en_US
dc.identifier.scopusauthoridWong, VWS=7202525502en_US
dc.identifier.scopusauthoridChan, PKS=7403497792en_US
dc.identifier.scopusauthoridWong, KT=7404760076en_US
dc.identifier.scopusauthoridWong, E=8313393800en_US
dc.identifier.scopusauthoridCockram, CS=7006379262en_US
dc.identifier.scopusauthoridTam, JS=24788939600en_US
dc.identifier.scopusauthoridSung, JJY=24473715000en_US
dc.identifier.scopusauthoridLo, YMD=7401935391en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats